Companion Diagnostics Come Of Age
The US companion diagnostics sector is predicted to grow from $1.6 billion to $6.2 billion between 2015 and 2021, a CAGR of 25.3%, outpacing the IVD market growth fivefold. This rapid growth will be driven by the development of new targeted pharmaceutical products and moves by the FDA to quickly approve new treatments and diagnostics together.
You may also be interested in...
Executives emphasized the role of "comprehensive diagnostics" in its plan to establish a dominant position in immuno-oncology drugs at this years' American Society of Clinical Oncology annual meeting.
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Qiagen’s agreement Tokai Pharmaceuticals targets circulating tumor cells, and Myriad Genetics has extended its partnership with BioMarin Pharmaceutical focused on Myriad's myChoice HRD companion diagnostic.